Amy C. Willis, Ph.D. - Publications
Affiliations: | 2003 | Medical College of Georgia, Augusta, GA, United States |
Area:
Visual AttentionYear | Citation | Score | |||
---|---|---|---|---|---|
2004 | Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene. 23: 2330-8. PMID 14743206 DOI: 10.1038/Sj.Onc.1207396 | 0.309 | |||
2003 | Willis AC, Pipes T, Zhu J, Chen X. p73 can suppress the proliferation of cells that express mutant p53. Oncogene. 22: 5481-95. PMID 12934108 DOI: 10.1038/Sj.Onc.1206505 | 0.337 | |||
2003 | Nozell S, Wu Y, McNaughton K, Liu G, Willis A, Paik JC, Chen X. Characterization of p73 functional domains necessary for transactivation and growth suppression. Oncogene. 22: 4333-47. PMID 12853970 DOI: 10.1038/Sj.Onc.1206470 | 0.562 | |||
2003 | Dohn M, Nozell S, Willis A, Chen X. Tumor suppressor gene-inducible cell lines. Methods in Molecular Biology (Clifton, N.J.). 223: 221-35. PMID 12777734 DOI: 10.1385/1-59259-329-1:221 | 0.441 | |||
2003 | Chen X, Liu G, Zhu J, Jiang J, Nozell S, Willis A. Isolation and characterization of fourteen novel putative and nine known target genes of the p53 family. Cancer Biology & Therapy. 2: 55-62. PMID 12673118 DOI: 10.4161/Cbt.180 | 0.614 | |||
2002 | Willis AC, Chen X. The promise and obstacle of p53 as a cancer therapeutic agent. Current Molecular Medicine. 2: 329-45. PMID 12108946 DOI: 10.2174/1566524023362474 | 0.343 | |||
Show low-probability matches. |